StockDriftsStockDriftsTop 14 Aisling Capital Management LP Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| BBIO | BRIDGEBIO PHARMA INC | 72.48% | 4.59M | $341.8M | -9.82%(-500.00K) | $40.61(+93.82%) | 2026-06-30 | |
| GLUE | MONTE ROSA THERAPEUTICS INC | 7.98% | 1.56M | $37.6M | +0.00%(+0) | $22.34(-30.63%) | 2026-06-30 | |
| SNDX | SYNDAX PHARMACEUTICALS INC | 6.1% | 1.32M | $28.8M | +0.00%(+0) | $10.51(+88.79%) | 2026-06-30 | |
| CMPS | COMPASS PATHWAYS PLC | 4.3% | 1.43M | $20.3M | +0.00%(+0) | $6.84(+96.74%) | 2026-06-30 | |
| BCAX | BICARA THERAPEUTICS INC | 3.58% | 568.9K | $16.9M | +0.00%(+0) | $25.47(-4.67%) | 2026-06-30 | |
| BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | 1.64% | 1.02M | $7.8M | +0.00%(+0) | $10.94(-17.17%) | 2026-06-30 | |
| SRRK | SCHOLAR ROCK HLDG CORP | 0.9% | 77.0K | $4.2M | +0.00%(+0) | $36.33(+44.56%) | 2026-06-30 | |
| URGN | UROGEN PHARMA LTD | 0.84% | 108.0K | $4.0M | +0.00%(+0) | $21.69(+123.15%) | 2026-06-30 | |
| BMEA | BIOMEA FUSION INC | 0.64% | 2.05M | $3.0M | +0.00%(+0) | $7.34(-82.35%) | 2026-06-30 | |
| ACRS | ACLARIS THERAPEUTICS INC | 0.49% | 434.5K | $2.3M | +0.00%(+0) | $10.96(-47.24%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative |
|---|---|---|---|---|
| Top 20 Holdings Weighted | +44.84% | +203.87% | +5.03% | +27.84% |
| Top 20 Holdings Unweighted | +22.72% | +84.80% | +9.25% | +55.64% |
Aisling Capital Management LP reports $471.62M in US-listed equity holdings across 14 positions in its most recent 13F filing. Its largest disclosed positions are BBIO (72.5%), GLUE (8.0%) and SNDX (6.1%). The top 20 holdings account for 100% of reported assets. Its disclosed equity book has returned +203.87% on a three-year cumulative basis. Figures reflect the Q2 2026 filing.
Portfolio changes
Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.
Sign up free to track Aisling Capital Management LP, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Aisling Capital Management LP’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1766721). View Aisling Capital Management LP’s 13F filings on SEC